Biotalys shifts to 2G product, reduced headcount in completing strategic review

In Belgium, Biotalys completed a strategic review of the company by CEO Kevin Helash and the board of directors. The review leads to a shift to the second-generation AGROBODY technology to develop protein-based biocontrols for crop and food protection. This move to AGROBODY 2.0 entails organizational changes to concentrate resources on core R&D capabilities while focusing on obtaining registration for Biotalys’ first product candidate EVOCA. Biotalys’ AGROBODY platform is based on VHH-technology already successfully applied in the pharmaceutical industry and Biotalys is pioneering this technology for agriculture. By applying a discovery method based on defined molecular targets, Biotalys is now pursuing novel opportunities to identify potent bioactive ingredients for use in crop protection. This AGROBODY 2.0 approach will therefore become the main focus of the R&D organization. It has the potential to clearly differentiate the company’s protein-based biocontrols from other biological solutions thanks to a larger range of modes of action to fight agricultural pests and diseases. The company announced a major reduction in force in conjunction with the completion of the review. 

More on the story.